Less than 7% of cervical cancer patients in Kenya are getting the optimum treatment needed to eradicate the disease, leading to unnecessary deaths – a study by The University of Manchester scientists reveals.
Results from the research, which looked retrospectively at the treatment of women diagnosed with cervical cancer during a two year period, showed 18% of cervical cancer patients in the East African country died within two years of a diagnosis.
Dr Ian Hampson, from The University of Manchester’s Institute of Cancer Sciences who oversaw the research, said the findings, published in PLOS One this week, add further weight to the call to spend more on cancer screening and prevention in Kenya.
Cervical cancer is caused by infection with human papilloma virus (HPV) and is more than five times more prevalent in East Africa than the UK.
The Manchester researchers analysed treatment of 355 Kenyan women diagnosed with cervical cancer at the Departments of Gynaecology and Radiotherapy at Kenyatta National Hospital between 2008 and 2010. Of the 355 patients originally recorded, 146 (42%) disappeared during the two year period meaning they did not receive treatment. A further 64 (18%) of the remaining women died during the study period.
Dr Hampson said: “Our figures predict that less than 20% of those left will survive during the next two years. The late stage at which women get diagnosed, inaccurate assessments of the extent of the disease and long waiting times for treatment are all significant factors in this huge difference in survival rates between Kenya and the UK as well as poverty and lack of cancer awareness. Our study suggests simple, cost effective changes in hospital procedures to improve the situation.”
The research team are now looking for more funders to help improve cancer treatment in Kenya, like The American company Hologic who have provided free HPV and cervical screening equipment plus running costs.
Dr Innocent Orora Maranga, who carried out the research as part of his PhD under the supervision of Drs Ian and Lynne Hampson in Manchester and Dr Peter Gichangi in Nairobi, said: “I am constantly surprised how few people in the UK know about the extent of the cervical cancer problem in East Africa which has the highest incidence in the world.
“The main issue is that, like many other low income nations, Kenya does not have a cervical screening program to detect the disease in its earliest stages or even the resources to treat this appropriately.”
The research is funded by The Janice Cholerton Cancer and Postgraduate Studentship Fund, The Humane Research Trust, The International Atomic Energy Agency and Wellbeing of Women. Support from these and other charities including The Caring Cancer Research Trust, The Cancer Prevention Research Trust, United in Cancer Quest Cancer Research and The Charities Aid Foundation East Africa Medical Trust, has allowed the team to carry out free HPV testing and cervical screening on smears taken from 800 Kenyan women. Over 50 women found to have premalignant cervical disease and five with invasive cancer which would have gone undetected are now getting free treatment.
Dr Maranga, now consultant gynaecologist in Nairobi, has also established the Kenyan charity Cancer Research Trust- Kenya (CRT-K) with personal support from a UK philanthropist Ken Cholerton. CRT-K has contributed to the cost of cervical screening and also paid for the treatment costs of over 220 Kenyan women with advanced cervical cancer who could not afford this.
Dr Hampson, who is also part of Manchester Cancer Research Centre (MCRC) a partnership between the University, The Christie NHS Foundation Trust and Cancer Research UK, added: “We have established a unique close working relationship between physicians/care-givers working in Nairobi and scientists and physicians in Manchester which gives us a golden opportunity to make a real difference in the lives of many Kenyan women afflicted with this disease.
“We have made a fantastic start to tackling a very significant global health problem. We have assembled all the pieces of the engine – now all we need is the fuel to run it.”
- Ends -
Notes to Editors:
Dr Ian Hampson is available for interview, please contact: Alison Barbuti | Media Relations Officer | The University of Manchester
Tel. +44 (0)161 275 8383 | Mobile 07887 561 318 | Email: firstname.lastname@example.org
The paper is published in The Public Library of Science (PLOS) 30 October
PLOS ONE manuscript PONE-D-13-24489, “Analysis of factors contributing to the low survival of cervical cancer patients undergoing radiotherapy in Kenya.”
The University of Manchester
The University of Manchester, a member of the Russell Group, is one of the largest and most popular universities in the UK. It has 20 academic schools and hundreds of specialist research groups undertaking pioneering multi-disciplinary teaching and research of worldwide significance. According to the results of the 2008 Research Assessment Exercise, The University of Manchester is one of the country’s major research institutions, rated third in the UK in terms of ‘research power’. The University has an annual income of £807 million and is ranked 40th in the world and fifth in the UK for the quality of its teaching and impact of its research.